A detailed history of First Trust Advisors LP transactions in Replimune Group, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 19,849 shares of REPL stock, worth $253,868. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,849
Previous 16,943 17.15%
Holding current value
$253,868
Previous $152,000 42.76%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$8.09 - $11.23 $23,509 - $32,634
2,906 Added 17.15%
19,849 $217,000
Q2 2024

Aug 13, 2024

BUY
$5.01 - $9.46 $5,871 - $11,087
1,172 Added 7.43%
16,943 $152,000
Q1 2024

May 13, 2024

BUY
$6.87 - $9.31 $27,260 - $36,942
3,968 Added 33.62%
15,771 $128,000
Q4 2023

Feb 13, 2024

BUY
$6.75 - $16.18 $12,035 - $28,848
1,783 Added 17.79%
11,803 $99,000
Q3 2023

Nov 13, 2023

BUY
$15.96 - $22.18 $159,919 - $222,243
10,020 New
10,020 $171,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $631M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.